Frelii, Inc. Inks Agreement with Orn Health Inc. to Support Healthcare Franchisee Partners Incorporating Pharmacogentics Into Patient Treatment

Published on: June 10, 2019
Author: Amy Liu

Frelii Inc. (OTC PINK: FRLI) (“Frelii” or “the Company”) today announced the details of its recent agreement with Orn Health Inc. (Orn), a medical services provider, to license the Frelii exome and whole genome sequencing and artificial intelligence (AI) technology for use with new franchisee partners in their own medical practices for enhancing patient treatment resources.

Currently, Frelii provides a consumer-level DNA Kit Package™ and report with alignment specifically for OTC cannabis, CBD, supplements and nutraceuticals that can be disseminated directly to a consumer without the presence of a physician or licensed healthcare provider. Frelii has forged this partnership with Orn to create broader opportunities for the company within the medical and healthcare industries, specifically. Now they will be able to offer their more enhanced Medical Grade DNA Kit Package™ and report, inclusive of specific panels that can be selected only by a licensed physician or healthcare provider.

“Frelii delivers one of the most comprehensive and robust exome and whole-genome DNA sequencing and analysis services in the world to aid physicians with disease management, precision pharmaceutical or cannabinoid dosing and overall patient genetic profiling to aid in diagnosis and treatment,” said Ian Jenkins, CEO of Frelii Inc. “It does not, however, provide medical advice or treatment recommendations. In order for patients and individuals to get advice regarding their genetic predisposition to certain medical diseases or conditions, or their body’s ideal alignment with pharmacogenetic factors, a licensed healthcare provider or medical doctor must be involved to properly interpret and apply the data available through our enhanced medical grade package. This is why we have forged a partnership with Orn.”

Orn will be responsible for creating a network of franchisees that have secured licensed rights to access Orn’s platform of resources, which include: Frelii Medical Grade DNA Kit Package™ and reporting data, the Frelii DNA Wallet™ platform, a proprietary telehealth platform, ERM, proprietary treatment methodologies, marketing materials and billing support. Orn will include facilitating billing reimbursement through various insurance providers on behalf of franchisees. This will result in an interconnected grid of national and international healthcare facilities, hospitals groups, clinics, doctor networks and managed care facilities that will all be able to access and leverage state of the art precision medicine, precision dosing and precision treatment SOPs with the advanced genetic data provided through Frelii; all designed to help serve more patients while managing costs.

“Physicians need access to leading technologies that enable them to treat more patients accurately with advanced diagnostic and treatment resources, while still managing costs,” said Dr. Hans Jenkins, D.O., Principal Director and Founder of Orn Health Inc. and Chief Medical Officer of Frelii, Inc. “Pharmacogentics, when combined with advanced treatment SOPs and methodologies from Orn will give healthcare providers much better tools to effectively treat critical healthcare issues facing physicians today, such as the opioid addiction crisis.”

The current business strategy from Orn is to establish a strong network of franchise partners across the United States and Canada. From there, specific international target geographies will be considered. At present, Orn will maintain the franchises for Utah, Nevada and California. Among the first independent franchise target geographies being considered are Washington, Texas, Arizona and Oklahoma.

“Frelii anticipates a long and successful relationship with Orn,” said Leslie Norris, COO of Frelii and Board Director. “The business mission of Orn is in complete alignment with the core value proposition of Frelii. We know that patients and their physicians can achieve much better results together when they can ‘see’ the entire genetic profile of each individual. Issues such as those that will affect possible disease alignment and what type of pharmaceuticals and cannabinoids can be ideally absorbed effectively come into true focus when our unique human genome becomes a day to day element in diagnosis and treatment.”

About Orn Health Inc. and Hans Jenkins, D.O.

Orn Health Inc. is located in Farmington, UT and serves as both a primary care facility and headquarters for Orn. Dr. Hans Jenkins serves as Medical Director and Principle of Orn and was appointed as Frelii’s Chief medical Officer and to serve on the Board of Directors in March 2018. Dr. Jenkins is highly experienced in developing lifestyle and nutrition plans for patients seeking to optimize their long-term health through preventive care. His practice prioritizes preventive health education, medical screenings, and lifestyle modifications to obtain optimal health. Dr. Jenkins graduated from Weber State University, then earned his Doctor of Osteopathy (D.O.) degree from Arizona College of Osteopathic Medicine. Following medical school, Dr. Jenkins completed a family medicine internship at John C. Lincoln Hospital in Phoenix, Arizona. An honored veteran of the United States Air Force, Dr. Jenkins served more than four years as a flight surgeon during Operation Iraqi Freedom with two deployments to combat zones. Dr. Jenkins completed his family medicine residency program at St. Joseph’s Hospital in 2011. Dr. Jenkins is the Medical Director and a primary care physician at Orn in Farmington, Utah.

About Frelii Inc.

Frelii Inc. is a biotech company that uses human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome. The results are aligned and leveraged against its AI, as a means of creating a very strong and powerful data platform for use by the Health & Wellness, Healthcare, Medical Cannabis and Pharmaceutical industries. Frelii’s technology generates accurate and profoundly valuable insight into an individual’s DNA. The company provides DNA Kit Packages and customized reporting for consumers, patients and healthcare providers to ensure the ideal treatment, drugs and dosing are a prime “fit” to the individual. For more information, please visit Frelii (OTC PINK: FRLI) currently trades on the OTC Pink Open Market, which is operated by the OTC Markets Group. Investors can find Real-Time quotes and market information for the company on

Follow Frelii online at:

Frelii Facebook Page

Frelii Twitter Feed @livefrelii

Frelii Instagram Page @livefrelii

Frelii LinkedIn Page

Safe Harbor Statement:

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Source: Biospace

Cannabis Life Science